“a decreasing trend”

In contrast, the abundance of Actinobacteria showed a decreasing trend on day 1, with the abundance of the treatment group (0.256 ± 0.005) lower than that of the control group (0.381 ± 0.202) ( p = 0.344).

Overall, delay heart-mediastinum ratio (H/M) had no significant change, and washout rate (WR) showed a decreasing trend (delay H/M; pre 2.07 ± 0.46, post 2.05 ± 0.49, paired p = 0.348, WR; pre 36.1 ± 11.6%, post 33.6 ± 11.7%, paired p = 0.061).

The overall age-adjusted mortality rate (AAMR) in 1999 was 0.07 (95% CI 0.06 to 0.087) which remain stable till 2005 (0.071, 95% CI 0.06 to 0.082) with an APC of -0.034 (95% CI -4.30 to 4.4, p = 0.98) followed by a decreasing trend till 2008 with an AAMR of 0.05 (95% CI 0.04 to 0.058) with an APC of -11.51(95% CI -33.55 to 17.84, p = 0.35).

Trend analysis of the constituent ratio of the common type of primary glomerular disease IgAN was the most common type of PGD during the study period, whereas the proportion showed a decreasing trend ( Fig. 3 ) (APC, –0.9%; 95% CI, –2.9 to 1.1; p = 0.35) ( Supplementary Table 4 , 5 , available online).

Regarding rehabilitation-related complications, the incidence was 1.7% in the observation group versus 6.7% in the control group; although a decreasing trend was observed, the difference was not statistically significant ( P = .362).

High-dose SLBZS (20.14 g/kg) significantly reduced MDA content ( p < 0.01), with a decreasing trend observed in low-dose (5.04 g/kg) ( P = 0.3710) and medium-dose groups (10.07 g/kg) ( P = 0.0508), though not statistically significant.

Comparison of DTI and ASL measurements among early/mid-late PD patients and healthy subjects The substantia nigra (SN) FA values of early/mid-late PD patients were significantly lower than those in the healthy subjects ( Table 1 ), whereas there was no significant difference in FA-SN between the early PD and mid-late PD groups, although a decreasing trend existed with increasing modified Hoehn & Yahr scale (H&Y) stage ( p = 0.373; Table 1 ).

ALT was significantly lower in NRP-1 knockout mice after one injection (p = 0.0116), while AST showed a decreasing trend without statistical significance ( p = 0.3740).

When separate analysis was performed, non-responders (NR) displayed a decreasing trend of HbF levels during treatment ( p = 0.380), especially in HbF1 ( p = 0.114), although not statistically significant.

Coimmunostaining retinal organoid sections for calretinin, AP2 α , and Arl13b antibodies revealed a decreasing trend of ciliation in calretinin-positive amacrine cells during organoid development ( P = 0.382, One-way ANOVA; Figures 4(f) and 4(g) ).

In the PBNA, the 10–19 age group had significantly reduced titers ( β = –879, p = 0.012), while the >19 groups also showed a decreasing trend ( β = –519, p = 0.385), albeit without statistical significance.

In VCAM-1, a decreasing trend with the severity of allergic asthma was indicated (median 851.00 mild asthma vs. 765.70 moderate asthma vs. 698.15 severe and severe refractory asthma; p = 0.390).

However, the incidence of serious infection showed a decreasing trend (CD: RR 0.28, 95% CI 0.13–0.61; I 2 = 0%, p = 0.39; UC: RR 0.56, 95% CI 0.18–1.69; I 2 = 9%, p = 0.33; Supplementary Figure S5 ). 3.6.2 Maintenance therapy According to maintenance trial results, treatment of IBD patients with an IL-23 p19 inhibitor showed no connection with the significantly greater AEs compared with placebo (CD: RR 1.00, 95% CI 0.89–1.13; I 2 = 29%, p = 0.25; UC: RR 0.96, 95% CI 0.87–1.06; I 2 = 0%, p = 0.44; Supplementary Figure S6 ), but the results were not statistically significant.

There was no evidence of a decreasing trend in catch at 10 m (estimate = 0.085, ± SE = 0.098, p = 0.39) or 25 m (estimate = 0.096, ± SE = 0.082, p = 0.24).

The spleen index was elevated (SMD = 0.69; 95% CI [0.08, 1.29]; P = 0.03), IL-2 levels were increased (SMD = 1.71; 95% CI [0.88, 2.55]; P < 0.0001), IFN-γ levels were elevated (SMD = 1.14; 95% CI [0.72, 1.56]; P < 0.00001), while IL-6 levels showed a decreasing trend (SMD = -0.73; 95% CI [-2.42, 0.96]; P = 0.40), and TNF-α levels were elevated (SMD = 0.24; 95% CI [-0.81, 1.28]; P = 0.66).

In patients aged ≥60 years, the 1st_CGM was associated with a significant decrease in blood glucose levels over time (from 219 mg/dL to 156 mg/dL, p <0.05), in contrast with the 2nd_CGM that only showed a decreasing trend in blood glucose levels (from 171 mg/dL to 155 mg/dL, p =0.400), which was not significant.

Although not statistically significant, a decreasing trend in resistance to cephalosporins was observed in the post-pandemic period (cefazolin: 88.9% vs. 80.4%, p = 0.408; cefoxitin: 31.1% vs. 19.4%, p = 0.232; ceftazidime: 72.2% vs. 66.2%, p = 0.559; ceftriaxone: 81.6% vs. 66.2%, p = 0.101; cefepime: 64.8% vs. 57.4%, p = 0.489) (Table 5 ).

coli showed a significant effect ( p < 0.01) on body temperature, while the administration of mixed LAB strains ( p = 0.07) showed a decreasing trend in the body temperature, and the interaction between mixed LAB strains and E. coli showed no significant effect ( p = 0.41) on the body temperature in mice.

In addition, severe adverse events (≥grade IIIb according to the Clavien-Dindo classification) did not increase and showed a decreasing trend (1.2 vs 0.9 per month, p=0.41).

During the processing of yogurt, glycosylation of N 172 of platelet glycoprotein 4 was increased, but not to a significant extent (FC = 1.45, p = 0.10), while the other five N-glycosites showed a decreasing trend, which was also not significant (FC = 0.78–0.97; p = 0.41–0.82).

However, in patients receiving adjuvant treatment (radiotherapy or chemo-radiotherapy), although a decreasing trend was observed at 6 months, the decline was not statistically significant post-radiotherapy ( p = 0.414; adjusted p = 0.827) and chemo-radiotherapy ( p = 0.235; adjusted p = 0.235).

Compared with the control group, the Shannon index of the ESCC group showed a decreasing trend ( p = 0.4171; Figure 1B ), whereas the ES group owned a significantly higher Shannon index in comparison with the ESCC group ( p < 0.0001) and the control group ( p = 0.0022).

Notably, ASYLDs showed a decreasing trend globally from 2018 to 2021, APC = -0.04 (95% CI, -0.15 to 0.07, P = 0.42).

Although there was a decreasing trend of mean water content from the W1 to W4 treatment, no significant difference was found ( P = 0.43).

The CL tolerability analysis showed a decreasing trend from day 1 to day 21 in the total number of events per patient, with a discomfort level equal to or superior to grade 1 ( p = 0.43).